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Abstract
Background: Previous observations demonstrate that Cftr-null cells and tissues exhibit alterations in cholesterol 
processing including perinuclear cholesterol accumulation, increased de novo synthesis, and an increase in plasma 
membrane cholesterol accessibility compared to wild type controls. The hypothesis of this study is that membrane 
cholesterol accessibility correlates with CFTR genotype and is in part influenced by de novo cholesterol synthesis.
Methods: Electrochemical detection of cholesterol at the plasma membrane is achieved with capillary 
microelectrodes with a modified platinum coil that accepts covalent attachment of cholesterol oxidase. Modified 
electrodes absent cholesterol oxidase serves as a baseline control. Cholesterol synthesis is determined by deuterium 
incorporation into lipids over time. Incorporation into cholesterol specifically is determined by mass spectrometry 
analysis. All mice used in the study are on a C57Bl/6 background and are between 6 and 8 weeks of age.
Results: Membrane cholesterol measurements are elevated in both R117H and ΔF508 mouse nasal epithelium 
compared to age-matched sibling wt controls demonstrating a genotype correlation to membrane cholesterol 
detection. Expression of wt CFTR in CF epithelial cells reverts membrane cholesterol to WT levels further 
demonstrating the impact of CFTR on these processes. In wt epithelial cell, the addition of the CFTR inhibitors, Gly H101 
or CFTRinh-172, for 24 h surprisingly results in an initial drop in membrane cholesterol measurement followed by a 
rebound at 72 h suggesting a feedback mechanism may be driving the increase in membrane cholesterol. De novo 
cholesterol synthesis contributes to membrane cholesterol accessibility.
Conclusions: The data in this study suggest that CFTR influences cholesterol trafficking to the plasma membrane, 
which when depleted, leads to an increase in de novo cholesterol synthesis to restore membrane content.
Background
Recent studies have identified alterations in cholesterol
processing associated with cystic fibrosis (CF) [1-4]. The
hypothesis of this study is that plasma membrane choles-
terol accessibility as measured by electrochemical detec-
tion will correlate with CFTR genotype. Identifying this
relationship between this cholesterol measurement and
CFTR will help determine if this measurement can be
potentially utilized as a biomarker of CF. With the devel-
opment of new therapies targeting CFTR function, new
methods of identifying efficacy are needed that are reli-
able and non-invasive. Mechanistically, it is proposed that
rates of de novo cholesterol synthesis influence the mem-
brane cholesterol measurement.
The cystic fibrosis transmembrane conductance regu-
lator (CFTR) is a cAMP activated chloride channel of the
ATP binding cassette (ABC) family [5,6]. A structurally
similar protein within this family, ABCA1, is known to
mediate cholesterol transport across the plasma mem-
brane to high-density lipoprotein (HDL) [7,8]. The role of
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CFTR function in regulating cholesterol transport is
unclear, particularly with respect to how plasma mem-
brane cholesterol is regulated. It has been observed that
cultured CF cells, as well as nasal and tracheal epithelium
from CFTR null mice, exhibit a significant increase in
plasma membrane cholesterol accessibility [3]. Although
structurally similar to ABCA1, there is no evidence that
CFTR is capable of directly modulating cholesterol move-
ment. We have previously demonstrated that de novo
cholesterol synthesis is elevated in the lungs of Cftr -/-
mice [3]. Evidence does suggest that membrane choles-
terol content can be regulated by de novo synthesis [9,10].
Koter et al demonstrate that statin treatment reduces
membrane cholesterol content in erythrocytes from 2.24
+/- 1.69 to 1.17 +/- 0.75 mg cholesterol/mg protein, a 47%
reduction [9]. It is possible that increased membrane cho-
lesterol in CF plasma membrane is related to increased de
novo cholesterol synthesis.
Regardless of whether cholesterol processing changes
observed in CF cells and tissues are directly involved in
the pathology of CF, these cholesterol changes are poten-
tially good, accessible indirect markers of CF-related cell
signaling. The goal of this study is to determine if CFTR
genotype correlates with plasma membrane cholesterol
detection and to determine if de novo cholesterol synthe-
sis contributes to this measure. Data demonstrate a clear
CFTR genotype correlation with ΔF508 CFTR mice
exhibiting higher membrane cholesterol content and
increased de novo cholesterol synthesis relative to R117H
CFTR mice. Other studies demonstrate the relationship
between membrane cholesterol and CFTR by examining
restoration of wt CFTR in CF epithelial cells and examin-
ing the impact of acute CFTR inhibition.
Methods
Cell culture
Human epithelium 9/HTEo-cells over expressing the
CFTR R domain (pCEPR) and mock-transfected 9/
HTEo-cells (pCEP), the wild type phenotype, were a gen-
erous gift from the lab of Dr. Pamela B. Davis (Case West-
ern Reserve University). Cells were cared for as
previously described [11]. IB3-1 cells, human epithelial
with the delta F508 mutation (CF-phenotype), and S9
cells, IB3-1 cell stably transfected with the full-length wt
CFTR (control) were a generous gift from Pamela L. Zeit-
lin (Johns Hopkins University, Baltimore, MD). These
cells were grown at 37°C in 95% O2-5% CO2 on Falcon 10
cm diameter tissue culture dishes in LHC-8 Basal
Medium (Biofluids Camarillo, CA) with 5% FBS.
Mice
Mice homozygous for the ΔF508 CFTR mutation were
d e s c r i b e d  p r e v i o u s l y  [ 1 2 ] ,  a s  w e r e  m i c e  c a r r y i n g  t h e
R117H CFTR mutation [13]. Mice heterozygous for
CFTR expression (Cftrtm1Unc) were obtained from Jackson
Laboratories (Bar Harbor, MA). All mice were provided
by the CF Center animal core facility at Case Western
Reserve University. CFTR wild-type mice were siblings of
Cftr +/- mice. All mice were used between six and eight
weeks of age. All mice were used between six and eight
weeks of age and are back-crossed over ten generations
onto a C57Bl/6 background. Mice were cared for in
accordance with the Case Western Reserve University
IACUC guidelines by the CF Animal Core Facility.
Electrochemical measurements of cholesterol
Platinum microelectrodes are fabricated in house (4 μm
diamter wire for cell work and 100 μm diameter wire for
tissue measurements, Goodfellow Corp.) as described
[14,15]. Platinum wire is inserted into glass capillaries
(Kimax-51, Kimble products) and placed inside a heated
platinum coil. The glass is pulled to create a thin insulat-
ing layer on the platinum wire. The capillary microelec-
trodes are polished using a beveling machine (WPI, Inc.)
to produce a disk electrode. The microelectrodes are
immediately immersed in a 5 mM hexane solution of 11-
mercaptoundecanoic acid (95%, Aldrich Chem. Co) for 2
h to form a carboxylic acid terminated monolayer on the
electrode surface. Then, the microelectrodes are treated 2
mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
(EDC) (Sigma Chem. Co.) in 100 mM PBS solution (pH
7 . 4 )  f o r  3 0  m i n .  t o  a c t i v a t e  t h e  c a r b o x y l  g r o u p s  t o  a n
acylisourea intermediate. The modified electrode is
immersed in 1 mg/ml recombinant cholesterol oxidase
(WAKO Chemical USA, Inc., 42.0 units/mg) solution for
3 hrs allowing this intermediate to react with amine
immobilizing the enzyme on the electrode surface.
Data Acquisitions
Amperometric measurements are conducted using a
two-electrode cell and a voltammeter-amperometer
(Chem-Clamp, Dagan corp.). The three-pole Bessel filter
in the voltammeter-amperometer is set to 100 Hz. The
output is further processed using a noise-rejecting volt-
meter (model 7310 DSP, Signal Recovery Inc.) to digitally
filter 60-Hz noise. An Ag/AgCl (1 molar KCl) reference
e l e c t r o d e  i s  u s e d  f o r  a l l  e x p e r i m e n t s ,  a n d  t h e  a p p l i e d
potential is 780 mV versus NHE for all experiments. All
experiments are performed in 100 mM phosphate buffer
(pH 7.4) at 36°C. Single cells and excised tissue are cap-
t u r e d  b y  a  c a p i l l a ry  p r e p a r e d  i n  h o u s e  u s i n g  a n  I M - 6
microinjector (Narishige International USA, Inc.). The
electrode is initially positioned about 50 μm from the cell
surface or tissue inner edge for acquisition of baseline
data. The electrode is repositioned for contacting the bio-
logical sample and acquisition of electrode response.Fang et al. Respiratory Research 2010, 11:61
http://respiratory-research.com/content/11/1/61
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Measuring cholesterol synthesis in vivo
CFTRtm1Unc mice and the matched controls were given an
intraperitoneal injection (i.p.) (~ 24 μl per g body weight)
of deuterated saline (9 g NaCl in 1000 ml of 99% 2H2O,
Sigma-Aldrich, St. Louis, MO). After 8 h, mice were sac-
rificed using carbon dioxide. Blood was taken from the
heart and plasma collected. Whole lungs were collected.
Tissue samples were hydrolyzed in 1N KOH/70% ethanol
(v/v) for 2 at 70°C vortexing occasionally. Samples were
then evaporated to dryness, redissolved in 2 ml of water
and acidified using 12N HCl. Cholesterol was extracted
twice by addition of ethyl ether (3 ml). The pooled ether
extracts were evaporated to dryness under nitrogen and
then converted to the trimethylsilyl cholesterol deriva-
tives by reacting with 60 μl of bis(trimethylsilyl) trifluoro-
acetamide + 1% trimethylchlorosilane (Regis, Morton
Grove, IL) (TMS) at 60°C for 20 min. The 2H-labeling of
cholesterol was determined using an Agilent 5973N-
MSD equipped with an Agilent 6890 GC system. The
cholesterol was run on a DB17-MS capillary column (30
m × 0.25 mm × 0.25 μm). The oven temperature was ini-
tially held for 1 min at 150°C, then increased by 20°C per
min to 310°C and maintained for 8 min. The split ratio
was 20:1 with helium flow 1 ml per min. The inlet tem-
perature was set at 270°C and MS transfer line was set at
310°C. Under these conditions, cholesterol elutes at ~11.1
min. Electron impact ionization was used in all analyses
with selected ion monitoring of m/z 368-372 (M0-M4,
cholesterol), dwell time of 10 ms per ion.
The 2H-labeling of mice plasma water was determined
by exchange with acetone. Briefly, plasma was diluted 2-
fold with distilled water and reacted with 2 μl of 10 N
NaOH and 4 μl of a 5% (v/v) solution of acetone in ace-
tonitrile for 24 h. Acetone was extracted by addition of
600 μl of chloroform followed by addition of 0.5 g
Na2SO4. Samples were vigorously mixed and a small ali-
quot of the chloroform was transferred to a GC-MS vial.
Acetone was analyzed using Agilent equipment described
above. The oven temperature program was: 60°C initial,
increase by 20°C per min to 100°C, increase by 50°C per
min to 220°C and maintain for 1 min. The split ratio was
40:1 with a helium flow of 1 ml per min. The inlet tem-
perature was set at 230°C and the mass spectrometer
transfer line was set at 245°C. Acetone eluted at ~1.5 min.
The mass spectrometer was operated in the electron
impact mode (70 eV). Selective ion monitoring of m/z 58
and 59 was performed using a dwell time of 10 ms per
ion.
Calculation of cholesterol synthesis
Protocols followed in [3] were used. Briefly, rates of de
novo cholesterol synthesis were calculated using the for-
mula: Total labeling ([(M1 × 1) + (M2 × 2) + (M3 × 3) + (M4
× 4)])/n/2H-labeling of plasma water × time where Mi
represents isotope labeled isomeric species of cholesterol
(M1 being singly labeled, M2 doubly labeled) and "n" rep-
resents the number of exchangeable hydrogens, assumed
to be 25 for cholesterol.
Synthesis of Inactive-CFTRinh-172: 5-(N,N-
dimethylphenyl)methylene)-2-thioxo-3-[3-
(trifluoromethyl)phenyl]-4-thiazolidinone
Mixture of 2-thioxo-3-(3-trifluoromethyl phenyl)-4-thi-
azolidinone (110 mg, 0.4 mM, synthesized according to
Sonawane et al., [16], 4-(N,N-dimethyl)benzaldehyde (59
mg, 0.4 mM), and sodium acetate (50 mg) in glacial acetic
acid (1 ml) was refluxed for 4 h. Solvent was evaporated,
residue dissolved in ethyl acetate, filtered, and silica gel (1
g) was added. Compound on silica gel was purified by
normal phase flash chromatography to yield 68 mg yel-
low-orange crystals (yield 42%); mp: 224-226 °C; MS
(ES+) (m/z): [M+H]+  calculated for C19H15F3N2OS2,
409.4, found 409.3.
Results
Membrane cholesterol genotype comparison
Previous work has demonstrated that cultured cell mod-
els of CF and nasal and tracheal epithelium from Cftr -/-
mice exhibit an increase in membrane cholesterol con-
tent [3,17]. In order to determine if membrane choles-
terol measurement correlates with Cftr  genotype,
membrane cholesterol was measured in nasal epithelium
isolated from mice homozygous for either the R117H (R/
R) or the ΔF508 (ΔF/ΔF) CFTR mutations. Membrane
cholesterol content as measured by response ratio is ele-
vated in both R/R and ΔF/ΔF nasal epithelium (1.64 +/-
0.09 (R/R), p < 0.001; 2.14 +/- 0.10 (ΔF/ΔF), p = 0.01)
compared to age-matched sibling wt controls (Figure 1).
These data demonstrate that either a mild or severe dis-
ease related CFTR mutation will result in an increase in
membrane cholesterol, with a larger magnitude increase
in the ΔF/ΔF tissue. The magnitude increase in mem-
brane cholesterol in ΔF/ΔF mouse nasal tissue is identical
to what is observed in Cftr -/- nasal tissue [3]. This mea-
surement does not determine absolute cholesterol con-
tent, only cholesterol accessible to the electrode at the
outer leaflet of the plasma membrane. This increased
accessibility could be due to increased total content, cho-
lesterol displacement from the lipid bilayer, or efflux.
These data demonstrate that membrane cholesterol mea-
surements can differentiate between genotypes. WT
mice from the ΔF508 colony and the R117H colony were
directly compared and no difference in membrane cho-
lesterol measurement was observed.Fang et al. Respiratory Research 2010, 11:61
http://respiratory-research.com/content/11/1/61
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Effect of CFTR correction on membrane cholesterol content
The above data demonstrate that mutation of CFTR
results in an increase in membrane cholesterol content.
To verify if this effect is truly dependent on CFTR, mem-
brane cholesterol accessibility in the CF epithelial cell line
IB3 cells (ΔF508/W128X) and in S9 cells (IB3 cells stably
expressing wt CFTR) was measured. The goal of this
experiment is to determine if restoring wt CFTR expres-
sion in a CF cell will restore normal membrane choles-
terol homeostasis. As shown in Figure 2, S9 cell
membrane cholesterol content is significantly reduced
c o m p a r e d  t o  p a r e n t  I B 3  c e l l s .  T h e s e  d a t a  s u p p o r t  t h e
hypothesis that wt CFTR is required to maintain mem-
brane cholesterol homeostasis.
The effect of pharmacological inhibition of CFTR on 
membrane cholesterol content
D a t a  i n d i c a t e  a  c l e a r  i n f l u e n c e  o f  C F T R  g e n o t y p e  o n
membrane cholesterol content regulation. The mouse
models and cell models used model chronic alterations to
CFTR. The goal of this experiment is to determine the
impact of acutely modulating CFTR with pharmacologi-
cal inhibitors on membrane cholesterol. 9/HTEo-epithe-
lial cells were treated with the CFTR selective inhibitor
CFTRinh-172 (20 μM) for 24 h and membrane cholesterol
content measured electrochemically [16,18]. CFTR inhi-
bition under these conditions with this compound has
been reported to reproduce cell regulation profiles asso-
ciated with CF inflammation [19]. Contrary to cellular
Figure 2 Electrochemical determination of membrane cholester-
ol content in CFTR corrected CF cells. A) Representative traces of 
membrane cholesterol determination in IB3 CF cells and in CFTR-cor-
rected IB3 cells (S9). B) Quantification of responses between IB3 and S9 
cells. Responses are reported relative to wt response (response ratio) to 
indicate the fold-increase in response. Error bars represent SEM, n = 4 
for each. Significance determined by t test. *p < 0.001.
Figure 1 Electrochemical determination of membrane cholester-
ol content from mouse nasal epithelium. A, C) Representative traces 
of membrane cholesterol determination in excised nasal epithelium 
from Cftr R117H/R117H (R/R) mice and Cftr ΔF508/ΔF508 (ΔF/ΔF) mice, 
respectively, compared to sibling Cftr +/+ (wt) mice. B, D) Quantifica-
tion of responses between Cftr R/R and sibling Cftr +/+ (wt) nasal tissue 
and Cftr ΔF/ΔF nasal tissue compared to Cftr +/+ (wt) siblings. Respons-
es are reported relative to wt response (response ratio) to indicate the 
fold-increase in response. Error bars represent SEM, n = 4 for each. Sig-
nificance determined by t test. *p < 0.001. E) Representative traces of 
wt mice from the ΔF508 (ΔF) and R117H colonies. Mean response for 
wt mice in the ΔF and R117H colonies are 54.5 +/- 0.5 pC and 55.7 +/- 
1.5 pC, respectively.Fang et al. Respiratory Research 2010, 11:61
http://respiratory-research.com/content/11/1/61
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and in vivo CF models, acute CFTR inhibition resulted in
a dramatic reduction in membrane cholesterol accessibil-
ity (Figure 3). This finding suggested that increased mem-
brane cholesterol content in CF is actually a secondary
response. To test this hypothesis, 9/HTEo-cells were
exposed to CFTRinh-172 (20 μM) continuously for 72 h
being replenished with fresh drug every 24 h. Longer
CFTR inhibition r esults in a re bounding of membrane
cholesterol that begins to exceed baseline levels, although
not statistically significant at this time point (Figure 3).
These data suggest that alterations in cholesterol process-
ing in CF may be due to feedback mechanisms triggered
by initially diminished membrane cholesterol content in
response to lost CFTR function. However, membrane
cholesterol does not significantly exceed baseline levels
after 72 h. Pharmacological inhibition of CFTR with
CFTRinh-172 does not recapitulate the whole process of
CF alterations in cholesterol processing and the source of
increased membrane cholesterol content still needs to be
determined.
To assure that CFTRinh-172 was likely mediating the
drop in membrane cholesterol via CFTR inhibition, two
controls were performed. First, the influence of CFTRinh-
172 on CF-model pCEPR 9/HTEo-cells was examined.
The pCEPR cells are lacking CFTR function due to the
over expression of the regulatory (R) domain and have
been shown to exhibit the phenotype of increased mem-
brane cholesterol content compared to wt controls [3,11].
If the initial drop in membrane cholesterol content is due
to CFTR inhibition, CFTRinh-172 should have no effect in
p C E P R  c e l l s .  E x p o s u r e  o f  C F - m o d e l  p C E P R  c e l l s  t o
CFTRinh-172 (20 μM) for 24 h indeed has no impact on
membrane cholesterol content (Figure 4A, B). These data
Figure 4 Specificity of CFTR inhibition in regulating membrane 
cholesterol content. A) Representative traces of membrane choles-
terol determination in 9/HTEo-pCEPR (CF) cells after treatment with 
the CFTR inhibitor CFTRinh-172 for 24 h (red line) or cells with no treat-
ment (NT, black line). B) Quantification of responses between pCEPR 
(CF) cells with no treatment (NT) and cells with acute (24 h) addition of 
the CFTR inhibitor CFTRinh-172 (20 μM). Responses are reported relative 
to NT response (response ratio) to indicate the fold-difference in re-
sponse. Error bars represent SEM, n = 4 for each. Significance deter-
mined by t test. No significant difference was found. C) Representative 
traces of membrane cholesterol determination in 9/HTEo-pCEP (wt) 
cells after treatment with Inactive-CFTRinh-172 for 24 h (red line) or cells 
with no treatment (NT, black line). D) Quantification of responses be-
tween pCEP (wt) cells with no treatment (NT) and cells with acute (24 
h) addition of the Inactive-CFTRinh-172 (20 μM). Responses are reported 
relative to NT response (response ratio) to indicate the fold-difference 
in response. Error bars represent SEM, n = 4 for each. Significance de-
termined by t test. No significant difference was found.
Figure 3 Effect of 24 h CFTR inhibition and 72 h CFTR inhibition 
with CFTRinh-172 (20 μM) on membrane cholesterol content. A) 
Representative traces of membrane cholesterol determination in 9/
HTEo-cells after treatment with the CFTR inhibitor CFTRinh-172 for ei-
ther 24 h or 72 h with fresh inhibitor placed on cells every 24 h or cells 
with no treatment (NT). B) Quantification of responses between cells 
with no treatment (NT) and cells with acute (24 h) or chronic (72 h) 
CFTR inhibition. Responses are reported relative to NT response (re-
sponse ratio) to indicate the fold difference in response. Error bars rep-
resent SEM, n = 4 for each. Significance determined by ANOVA relative 
to NT samples. *p < 0.001.Fang et al. Respiratory Research 2010, 11:61
http://respiratory-research.com/content/11/1/61
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support the finding that the initial drop in membrane
cholesterol is due to acute CFTR inhibition, and further
suggest that the subsequent increase in membrane cho-
lesterol content in CF cells is due to a secondary feedback
response. A second control consisted of treating 9/HTEo-
cells with an inactive form of CFTRinh-172 (Inactive-
CFTRinh-172) to verify that some nonspecific drug inter-
action was not responsible for the decrease in membrane
cholesterol. As shown in Figures 4C and 4D, Inactive-
CFTRinh-172 had no influence on membrane cholesterol
content. These data strongly support the findings that
acute inhibition of CFTR function leads to decreased
membrane cholesterol content.
To confirm that inhibition of CFTR influences mem-
brane cholesterol content, the effect of a second pharma-
cological inhibitor of CFTR, Gly H101 (10 μM), was
examined. A similar, but slightly modified, electrochemi-
cal technique was used to test the influence of Gly H101
on membrane cholesterol. A background subtraction
a n a l o g  c h r o n o c o u l o m e t r y  m e t h o d  i s  u s e d  t o  q u a n t i f y
hydrogen peroxide production, which correlates to cho-
lesterol content. With the electrode held in contact with
the cell surface, several measurements reflecting mem-
brane cholesterol are collected. Consistent with CFTRinh-
172 results, cells treated with Gly H101 for 24 h demon-
strate a significant decrease in cholesterol content that
rebounds to baseline levels by 72 h (Figure 5).
Heterozygote effect
The finding that acute CFTR inhibition leads to signifi-
cant membrane cholesterol depletion, coupled with the
observations that both mild and severe CFTR mutations
result in elevated membrane cholesterol content,
prompted the examination of what the effect of CFTR
heterozygosity woud be on membrane cholesterol acces-
sibility. The goal of the study was to determine if there is a
C F T R  d o s e  e f f e c t  w i t h  Cftr  +/- mice having elevated
membrane cholesterol intermediated between wt and CF
models, or if there was actually a loss of membrane cho-
lesterol as seen with acute CFTR inhibition. As shown in
Figure 6, Cftr +/- nasal epithelium exhibits a relatively
slight, but significant loss of membrane cholesterol (0.87
+/- 0.04 fold compared to wt, p < 0.01). These data sug-
gest that CFTR heterozygosity impacts cholesterol move-
ment to the plasma membrane. These data can be
consistent with the pharmacological inhibition of CFTR
data in that CFTR may be involved in cholesterol move-
ment to the membrane and reduced membrane choles-
terol triggers a feedback response. The slight drop in
membrane cholesterol content in Cftr  +/- nasal tissue,
although statistically significant, is likely physiologically
insufficient to trigger a compensatory mechanism to
increase cholesterol synthesis.
Increased lung cholesterol synthesis in two different mouse 
models of CF
Lange and Steck described a relationship between mem-
brane cholesterol content and the regulation of choles-
terol synthesis [20]. A potential mechanism for the
rebound of membrane cholesterol observed with phar-
macological CFTR inhibitors would be an increase in de
novo  synthesis in response to transient decreases in
membrane cholesterol content in response to dysfunc-
tional CFTR. A prediction based on this mechanism
would be that cholesterol synthesis should correlate with
CFTR genotype in relation to membrane cholesterol con-
Figure 5 Effect of 24 h CFTR inhibition and 72 h CFTR inhibition 
with Gly H101 (20 μM) on membrane cholesterol content. A) Rep-
resentative traces of membrane cholesterol determination in 9/HTEo-
cells after treatment with the CFTR inhibitor Gly H101 for either 24 h or 
72 h with fresh inhibitor placed on cells every 24 h or cells with no 
treatment (NT). B) Quantification of responses between cells with no 
treatment (NT) and cells with acute (24 h) or chronic (72 h) CFTR inhi-
bition. Responses are reported relative to NT response (response ratio) 
to indicate the fold-difference in response. Error bars represent SEM, n 
= 4 for each. Significance determined by ANOVA relative to NT sam-
ples. *p < 0.001.Fang et al. Respiratory Research 2010, 11:61
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tent in the airways. To test this prediction, lung de novo
cholesterol synthesis in ΔF/ΔF and R/R mice was mea-
sured. Deuterium incorporation into cholesterol of spe-
cific tissue was determined by GC/MS analysis. Results
reveal a 1.6 + 0.2 fold (p = 0.009) increase in % new cho-
lesterol synthesis in the lung of ΔF/ΔF mouse lung com-
pared to controls and a 1.2 + 0.1 fold (p = 0.04) in the
lungs of R/R mice compared to respective controls (Fig-
ure 7A). Increased cholesterol synthesis in the lungs of
two other CF mouse models validates our previous find-
ings in Cftr-/- mouse tissue [3], and a more severe CFTR
mutation correlates with greater increases in the rate of
cholesterol synthesis in the lung, supporting the impor-
tance of CFTR function in influencing cholesterol syn-
thesis.
Figure 6 Comparison of nasal epithelium membrane cholesterol 
content in Cftr +/+ and Cftr +/- mice. A) Representative traces of 
membrane cholesterol determination in excised nasal epithelium from 
Cftr +/+ (wt) mice and Cftr +/- mice. B) Quantification of electrochemi-
cal membrane cholesterol determination between Cftr +/+ (wt) nasal 
tissue and Cftr +/- nasal tissue. Responses are reported relative to wt re-
sponse (response ratio) to indicate the fold-difference in response. Er-
ror bars represent SEM, n = 4 for each. Significance determined by t 
test. *p = 0.008.
Figure 7 De novo cholesterol synthesis in CF mouse lung com-
pared to matched controls. A) Deuterium incorporation into newly 
synthesized tissue cholesterol was measured by GC/MS. Data is nor-
malized to each tissue wt control (represented by dotted line) and re-
ported as fold increase of % newly synthesized cholesterol/8 h. Filled 
bars represent ΔF/ΔF mice and open bars represent R/R mice. The 
number of replicates is shown in parenthesis above each bar and rep-
resents individual assay on multiple tissue samples obtained over 3 ex-
periments. *p < 0.05, #p < 0.01. B) Increased SRE response in CFTRinh-
172 treated control epithelial cells. 9/HTEo-pCEP (wt) cells were incu-
bated in serum free conditions for 24 h with or without 20 μM CFTRinh-
172 (INH-172) in serum free media for an additional 24 h. 9/HTEo-pCEP 
are open bars. Data are normalized to serum free NT control levels over 
3 experiments. Number (n) of samples is in parenthesis above each bar. 
Significance was determined by t test. Error bars represent SEM. * p < 
0.0001.Fang et al. Respiratory Research 2010, 11:61
http://respiratory-research.com/content/11/1/61
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Increased sterol response element (SRE) activation in 
response to CFTR inhibition
The above data suggest that CFTR genotype influences
the regulation of de novo cholesterol regulation. Based on
the above results it is predicted that treatment with CFTR
inhibitors should result in SRE activation. To test this pre-
diction, the effect of the CFTR inhibitor CFTRinh-172 on
SRE activation was examined utilizing an SRE-luciferase
construct. The construct contains SRE binding sites of
the promoter region of HMG-CoA synthase, the rate-
limiting enzyme regulating de novo cholesterol synthesis.
9/HTEo-cells were treated with 20!M CFTRinh-172 for 24
hours and assayed for SRE responsiveness. Control epi-
thelial cells treated with CFTRinh-172 showed a signifi-
cant increase of 2.8 + 0.3 fold (p < 0.0001) above control
levels (Figure 7B). These data are consistent with the in
vivo data above that loss of CFTR function leads to an
increase in de novo cholesterol synthesis.
Regulation of membrane cholesterol content by 
cholesterol synthesis in CF
The above data suggest a relationship between choles-
terol synthesis and membrane cholesterol content. To
test directly whether cholesterol synthesis impacts mem-
brane cholesterol content in CF cells and tissues, choles-
terol synthesis was inhibited with two unrelated
compounds, mevastatin and resveratrol, and the impact
on membrane cholesterol content examined. Only CF
cells were tested due to increased cholesterol signal at the
membrane with electrochemical detection. It is antici-
pated that the relationship between cholesterol synthesis
and membrane cholesterol accessibility would be the
same in wt cells, but this relationship was not tested
directly. Resveratrol was used because it is unrelated to
the statin compounds and Do et al have shown that res-
veratrol reduces cholesterol synthesis in vivo in apo E-
deficient mice through an AMP kinase (AMPK)-depen-
dent mechanism [21]. In order to test the hypothesis that
cholesterol synthesis contributes to membrane choles-
terol content in CF cells, the impact of mevastatin and
resveratrol on membrane cholesterol was examined. CF
model 9/HTEo-pCEPR cells were chosen since they are
cultured cells that exhibit the increased membrane cho-
lesterol that is observed in vivo in mouse models of CF
[6]. Cells were treated with either mevastatin (50 μM) or
resveratrol (50 μM) for 24 hours. Resveratrol treated CF
epithelial cell membrane cholesterol content is signifi-
cantly decreased (0.06 pA +/- 0.01, p-value <0.001) com-
pared to untreated cells (Figure 8A, B). The control trace
represents a measurement taken with a bare electrode
not modified with cholesterol oxidase to confirm the cho-
lesterol sensitivity of the measurement. CF-model epithe-
lial cells treated with mevastatin show a decrease in
plasma membrane cholesterol content similar to what is
seen with resveratrol treatment (0.07 pA +/- 0.01, p-value
<0.001) (Figure 8C, D). In the presence of AMPK inhibi-
tion (AMPKi compound C, 10 μm for 24 h), the resvera-
trol-mediated drop in membrane cholesterol is blocked
(1.07 +/- 0.09 fold over RSV treated 9/HTEo- pCEPR
(CF) epithelial cells, p-value <0.001) (Figure 8E, F).
In vivo modulation of membrane cholesterol content by 
resveratrol in CF mice
The cell lines used for the studies above were chosen
since they are known to exhibit CF-related alterations to
cholesterol accumulation and membrane cholesterol [6].
However, they are a clonal cell line that may not com-
Figure 8 Role of cholesterol synthesis in modulating membrane 
cholesterol content. (A) Membrane cholesterol content, measured as 
current (pA, picoamps), is decreased in resveratrol (RSV) treated 9HTEo-
pCEPR (CF) epithelial cells. Control experiment is done using bare Pt on 
untreated cells. (B) Resveratrol treated CF epithelial cells show de-
creased membrane cholesterol content (0.06 pA +/- 0.01 *p-value 
<0.001) compared to untreated cells. Data are shown as mean of four 
separate experiments. (C and D) Mevastatin (MEV) treated 9HTEo-
pCEPR (CF) epithelial cells show a similar significant decrease in mem-
brane cholesterol content (0.07 pA +/- 0.01 *p-value <0.001). Data are 
shown as mean of four separate experiments. Error bars are SEM in all 
experiments. (E) Resveratrol's ability to decrease membrane cholester-
ol content is blocked in the presence of the AMPKi. Current measured 
as picoamps (pA). (F) AMPKi increases membrane cholesterol content 
above baseline compared to resveratrol treated cells (1.07 +/- 0.09, *p 
< 0.001). Untreated CF cells normalized to one. Data are from three 
separate experiments. Error bar is SEM.Fang et al. Respiratory Research 2010, 11:61
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pletely reflect physiological responses. To determine
whether the same intervention would have a similar
impact on membrane cholesterol in a more physiologi-
cally relevant model, CFTR deficient (CFTRtm1Unc) mice
and wt controls were treated with resveratrol for 3-6
weeks. Resveratrol was placed in the drinking water as
previously described [21] and the average amount of res-
veratrol consumed was 15-28 mg/kg/day per mouse. The
drug was tolerated well by all treatment groups. Resvera-
trol was chosen over mevastatin for ease of administra-
tion over an extended period of time and since it has been
shown to be effective in vivo in mice previously [21]. All
mice had adequate weight gain and lived until the time of
sacrifice. After sacrifice, membrane cholesterol accessi-
bility was determined from excised nasal epithelial in wt
and  CFTRtm1Unc  mice (Cftr -/-) in the presence and
absence of resveratrol. CF mice exhibited a decrease in
membrane cholesterol detection in response to resvera-
trol compared to sibling untreated mice (Figure 9) (CF
treated: 2.08 +/- 0.05 nC v. CF control: 1.56 +/- 0.03 nC),
p-value 0.05, n = 3). Membrane cholesterol detection also
decreased in wt mice treated with resveratrol (wt treated:
Figure 9 In vivo modulation of cholesterol in CF and wt mice with resveratrol. Membrane cholesterol measurement in Cftr -/- mouse (A) nasal 
epithelium and in Cftr +/+ mouse (B) nasal epithelium in response to in vivo exposure to resveratrol (drug treated, RES) (15-28 mg/kg body weight) for 
3 to 6 weeks. Representative tracings of electrochemical detection of membrane cholesterol are shown. Shown are three separate tracings (separate 
electrodes) from tissue from a single mouse. C) Tissues from three treated and three untreated Cftr -/- mice were examined by eight separate elec-
trodes and means represented in bar graph. Tissues from three treated and three untreated Cftr +/+ mice were examined by six separate electrodes 
and means represented in bar graph *Significance determined from n = 3, p-value < 0.05 as determined by t-test.Fang et al. Respiratory Research 2010, 11:61
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0.25 +/- 0.02 nC v. wt control: 0.42 +/- 0.01 nC), p-value
0.05, n = 3). The magnitude of response to resveratrol in
CF mice (0.52 nC) is greater than observed in wt (0.17
nC), likely due to the increased signal in CF tissues and
increased cholesterol synthesis. These data support the
above cellular studies and demonstrate that cholesterol
homeostasis is responsive to resveratrol in vivo and that
electrochemical detection of membrane cholesterol is
capable of monitoring responses.
Cholesterol synthesis
To verify that mevastatin and resveratrol do inhibit cho-
lesterol synthesis, cholesterol synthesis was measured in
CF-model 9/HTEo-pCEPR epithelial cells by deuterium
labelling. Resveratrol treated CF cells exhibit a 20 percent
decrease in cholesterol synthesis compared to vehicle
treated cells (0.80 +/- 0.03 fold below untreated cells, p-
value 0.005). Mevastatin, as a positive control, demon-
strates a similar decrease in cholesterol synthesis in CF
epithelial cells (Figure 10A).
HMG-CoAR expression in resveratrol treated CF epithelial 
cells
To further verify the direct measures of cholesterol syn-
t h e s i s  a b o v e ,  a n  i n d i r e c t  m e a s u r e  o f  b i o c h e m i c a l
response to reduced cholesterol synthesis was examined.
A response to decreased cholesterol synthesis is up-regu-
lation of the sterol response element (SRE) pathway to
increase the expression of synthesis enzymes such as
HMG-CoAR. HMG-CoAR mRNA levels were examined
b y  R T - P C R  i n  r e s p o n s e  t o  r e s v e r a t r o l  i n  C F  m o d e l
9HTEo-pCEPR epithelial cells. A 2.6 fold increase in
HMG-CoAR mRNA levels is seen in resveratrol treated
CF cells (2.6 +/- 0.6 fold over untreated cells, p-value
0.025) compared to untreated CF cells (Figure 10B). This
finding is consistent with findings of cholesterol synthesis
inhibition by resveratrol. A similar increase in HMG-
CoAR expression is seen in mevastatin treated cells as a
positive control. These results support the findings that
resveratrol inhibits cholesterol synthesis
Discussion
Membrane cholesterol is capable of modulating a variety
of cellular functions including the regulation of ion chan-
nels such as ENaC and the formation of signaling com-
plexes [22]. In addition to intracellular perinuclear
accumulation of free cholesterol, our previous work has
identified a CF-related increase in membrane cholesterol
accessible to electrochemical detection and in increase in
de novo cholesterol synthesis [3]. Excess cholesterol can
be stored in membrane fractions and initially it was
thought that excess membrane cholesterol in CF cells was
the result of passive diffusion of excess cholesterol to the
membrane. Given the potential importance of chronic
alterations in membrane cholesterol and de novo synthe-
sis, the goal of this manuscript is to determine if CFTR
genotype influences these outcome measures. Regardless
if cholesterol-processing alterations prove to be critical to
CF pathogenesis, cholesterol measurements could prove
to be important biomarkers for CF-related cellular pro-
cesses that are important to pathogenesis.
Presented data demonstrate that membrane cholesterol
is responsive to CFTR genotype. R/R mice exhibit a 1.6-
fold increase in membrane cholesterol content in nasal
Figure 10 Cholesterol synthesis and HMG-CoAR mRNA expres-
sion in CF epithelial cells. (A) Cholesterol synthesis decreases by 20% 
in resveratrol treated 9HTEo-pCEPR (CF-model) epithelial cells com-
pared to vehicle (DMSO) treated cells (0.8 +/- 0.03 fold below untreat-
ed cells *p-value <0.01). Mevastatin treated CF epithelial cells show a 
similar decrease in cholesterol synthesis compared to vehicle treated 
CF epithelial cells (0.78 +/- 0.05, *p-value 0.04). Data are the mean of 
three separate experiments. (B) HMG-CoAR mRNA expression in res-
veratrol (RSV) treated 9HTEo-pCEPR CF-model epithelial cells. An in-
crease in HMG-CoAR mRNA levels is seen with resveratrol (50 μm, 24 h) 
treatment (2.6 +/- 0.6 fold over untreated cells, *p-value 0.03). Mevas-
tatin (MEV) used as a positive control shows a similar increase in HMG-
CoAR expression (3.172 +/- 0.1 fold over untreated cells, *p-value 0.04). 
Data are the mean of three separate experiments. Error bars are SEM. 
Mann-Whitney rank sum test used where normality test failed.Fang et al. Respiratory Research 2010, 11:61
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epithelium compared to sibling wt mice, whereas, ΔF/ΔF
mice exhibit a 2.1-fold increase. Interestingly, acute 24 h
CFTR inhibition with either CFTRinh-172 or Gly H101
results in a decrease in membrane cholesterol content.
However, 72 h exposure to either CFTR inhibitor (replen-
ished every 24 h) results in a rebound in cholesterol con-
tent suggesting a secondary cellular response to lost
CFTR function is influencing membrane cholesterol reg-
u l a t i o n .  T h e  r e b o u n d  e f f e c t  d o e s  n o t  l e a d  t o  e l e v a t e d
membrane cholesterol as seen in CF cells and tissues [3],
indicating that the conditions tested here are not com-
pletely replicating the CF situation. The lack of excess
cholesterol in response to acute CFTR inhibition is unex-
plained. One possible explanation for observed results is
that 72 h pharmacological inhibition of CFTR does not
lead to sufficient free cholesterol accumulation to be dis-
tributed to the plasma membrane.
Mechanistically, de novo cholesterol synthesis is at least
a  c o n t r i b u t i n g  f a c t o r  t o  m e m b r a n e  c h o l e s t e r o l .  D i r e c t
measurement of cholesterol synthesis reveals that lungs
from R/R mice make significantly less cholesterol than
ΔF/ΔF mouse lungs, although cholesterol synthesis in
b o t h  g e n o t y p e s  i s  e l e v a t e d  c o m p a r e d  t o  r e s p e c t i v e  w t
controls. This ratio is consistent with relative changes in
membrane cholesterol content. Also, two inhibitors of
cholesterol synthesis, mevastatin and resveratrol, reduce
membrane cholesterol content in CF cells. In vivo treat-
ment with resveratrol also reduces nasal membrane cho-
lesterol in Cftr -/- mice.
The increased cholesterol synthesis we have observed
in CF cells and tissues is a likely contributor to increased
membrane cholesterol content in CF, but not likely the
sole contributor. The model proposed by Lange and Steck
[20] fits the rebound effect we see with the two CFTR
inhibitors. This model also fits our data as to why the 72 h
cholesterol content does not exceed baseline levels as
increased synthesis would be expected to only normalize
membrane content according the to the Lange and Steck
model. If cholesterol synthesis in response to impeded
cholesterol transport to the plasma membrane is insuffi-
cient to drive the excess plasma membrane cholesterol
seen in CF, then what is responsible? As a model we pro-
pose that mutations in CFTR disrupt cholesterol move-
ment to the plasma membrane likely through disruption
of endosomal trafficking, either directly or indirectly,
which is consistent with cholesterol accumulation
reported in CF cells [1-4]. This disruption leads to a
chronic increase in de novo cholesterol synthesis as pre-
dicted by the Lange and Steck model. Finally, as free cho-
lesterol accumulates in endosomes/lysosomes of CF cells,
excess cholesterol is stored in the plasma membrane lead-
ing to excess plasma membrane cholesterol observed in
CF cells and tissues. This excess storage is likely not
achieved in 72 h CFTR inhibitor treatment accounting
for the lack of CF-like membrane cholesterol increases.
Conclusions
The conclusion of this study is that the measurement of
membrane cholesterol accessibility to electrochemical
detection is influenced by CFTR. CFTR genotype corre-
lations with the measurement, reversion to wt levels in
CF cells with the introduction of wt CFTR, and pharma-
cological manipulation of CFTR with two separate inhibi-
tors influencing membrane cholesterol all point to a key
role of CFTR in modulating this phenotype. It is also con-
cluded that de novo cholesterol synthesis contributes sig-
nificantly to the regulation of membrane cholesterol. The
initiating step in CF-related alterations of cholesterol
homeostasis appears to be loss of a CFTR-mediated
movement of cholesterol to the plasma membrane fol-
lowed by a subsequent increase in de novo cholesterol
synthesis. The mechanism by which CFTR influences
movement of cholesterol to the plasma membrane is
unknown and under investigation. A candidate mecha-
nism being explored is CFTR function may influence
endosomal trafficking. Multiple reports demonstrate
CFTR presence in the endocytic pathway, but any rela-
tionship to lipid trafficking is speculative [23-25]. Our
previous data suggest that a localized increase in cAMP
signaling is a strong candidate as a regulator of this sys-
tem in CF [1]. Also unknown is the driving force for the
ultimate increase in membrane cholesterol accessibility.
One possibility is an increase in cholesterol efflux. We
have measured total cholesterol in Cftr ΔF/ΔF mouse liv-
ers and in the CF-model 9/HTEo-pCEPR cells and nei-
ther exhibits a significant increase in total cholesterol
compared to respective controls (not shown). These data
may indicate that CF cells have elevated cholesterol efflux
that could potentially be represented in the electrochemi-
cal detection data as discussed above. Our previous work
has demonstrated an increase of expression of the choles-
terol transport protein NPC1 in CF cells [4]. One of the
roles of NPC1 is the transport of cholesterol to the
plasma membrane from endosomes [26]. The role of
increased NPC1 expression in CF cells perhaps in
response to cholesterol accumulation is also being
explored as a potential mechanism leading to increased
cholesterol accessibility at the plasma membrane.
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